What is the current Targeted PSMA Radionuclide Drug Conjugates market size?

The current market size is approximately USD 1.2 billion as of 2023.

What are the key drivers of the Targeted PSMA Radionuclide Drug Conjugates market?

Increasing cancer prevalence and advances in radiopharmaceuticals drive the market.

What are the major challenges facing the Targeted PSMA Radionuclide Drug Conjugates market?

High development costs and regulatory hurdles are significant challenges.

Which regions are expected to lead the Targeted PSMA Radionuclide Drug Conjugates market?

North America and Europe are expected to be regional leaders.

Who are the top companies in the Targeted PSMA Radionuclide Drug Conjugates market?

Companies like Bayer and Novartis are key players in the market.

What future opportunities exist in the Targeted PSMA Radionuclide Drug Conjugates market?

Emerging markets and innovative technologies offer future growth opportunities.

How will technology impact the Targeted PSMA Radionuclide Drug Conjugates market?

Advances in imaging and dosing technologies will improve treatment outcomes.

What is the current regulatory landscape for the Targeted PSMA Radionuclide Drug Conjugates market?

Stringent regulations and approvals are required for market entry.

What is the future outlook for the Targeted PSMA Radionuclide Drug Conjugates market?

The market is expected to experience significant growth due to increasing demand.

Targeted PSMA Radionuclide Drug Conjugates Growth Trends & Strategic Outlook 2033

Targeted PSMA Radionuclide Drug Conjugates by Application (Hospital, Specialist Clinic, Other), by Types (Diagnostic, Therapeutic), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 11, 2025Updated: Jun 8, 2026

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 11, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Targeted PSMA Radionuclide Drug Conjugates Market Overview

The Targeted PSMA Radionuclide Drug Conjugates market refers to the industry involved in the development and distribution of targeted therapies using Prostate-Specific Membrane Antigen (PSMA) radionuclide drug conjugates for the treatment of prostate cancer. As the Targeted PSMA Radionuclide Drug Conjugates market size is expected to grow significantly, driven by increasing demand for effective cancer treatments, the growth outlook and market forecast are crucial for industry stakeholders. The industry expansion is anticipated to be driven by advancements in technology, regulatory approvals, and changing consumer behavior, with the global market estimated to be around $1.4 billion in 2025.

Loading chart…

The Targeted PSMA Radionuclide Drug Conjugates market is expected to grow at a compound annual growth rate (CAGR) of around 21% from 2026 to 2033, driven by macro drivers such as increasing cancer prevalence, rising healthcare expenditure, and growing demand for personalized medicine. Key forces shaping the industry include technology shifts towards more effective and targeted therapies, regulatory approvals and guidelines, and changing consumer behavior towards more informed and proactive healthcare decisions. The largest region is expected to be North America, while the fastest-growing region is anticipated to be the Asia-Pacific region, driven by increasing healthcare infrastructure and growing demand for cancer treatments.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.72 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; Telix Pharmaceutical; Lantheus; University of California; Grand Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Targeted PSMA Radionuclide Drug Conjugates market is poised for significant growth, driven by increasing demand for effective treatments for prostate cancer. The market dynamics are influenced by various factors, including technological advancements, regulatory approvals, and shifting consumer preferences.

Growth Drivers2 items

Advances in radiopharmaceuticals and nuclear medicine are driving the development of more effective Targeted PSMA Radionuclide Drug Conjugates, leading to increased adoption and growth in the market size

The growth forecast for the Targeted PSMA Radionuclide Drug Conjugates market is positive, with rising incidence of prostate cancer and increasing awareness about the benefits of targeted therapies

Restraints2 items

High development costs and stringent regulatory requirements are limiting the entry of new players in the Targeted PSMA Radionuclide Drug Conjugates market, thereby restraining market growth

The availability of alternative treatment options, such as hormone therapy and chemotherapy, is also hindering the growth of the Targeted PSMA Radionuclide Drug Conjugates market size

Opportunities2 items

The increasing focus on personalized medicine and precision oncology is creating new opportunities for Targeted PSMA Radionuclide Drug Conjugates manufacturers to develop tailored treatments for specific patient populations

The growing demand for effective and safe treatments for prostate cancer is driving the adoption of Targeted PSMA Radionuclide Drug Conjugates, presenting a significant opportunity for market players to expand their product offerings

Challenges2 items

The Targeted PSMA Radionuclide Drug Conjugates market is facing challenges related to the supply chain, including the availability of raw materials and the complexity of the manufacturing process

The pricing pressure and reimbursement issues are also affecting the profitability of Targeted PSMA Radionuclide Drug Conjugates manufacturers, making it essential for companies to develop strategies to mitigate these challenges

Market Segmentation

Loading chart…

The Targeted PSMA Radionuclide Drug Conjugates segmentation by application includes various sectors that contribute to the overall market size. This segmentation is crucial in understanding the market taxonomy and identifying opportunities for growth. The main applications of Targeted PSMA Radionuclide Drug Conjugates include prostate cancer treatment, research and development, and diagnostics. Each of these applications has a significant impact on the market, with prostate cancer treatment being the largest contributor.

The types of Targeted PSMA Radionuclide Drug Conjugates include Actinium-225, Lutetium-177, and Radium-223. These types are further divided into subtypes, which are used in various applications. For instance, Actinium-225 is used in prostate cancer treatment, while Lutetium-177 is used in research and development. Understanding these types and subtypes is essential in analyzing the market and identifying trends and opportunities.

Targeted PSMA Radionuclide Drug Conjugates Segmentation Breakdown7 items

Application

Hospital

Specialist Clinic

Other

Types

Diagnostic

Therapeutic

Regional Insights

Loading chart…

The Targeted PSMA Radionuclide Drug Conjugates market growth is expected to vary across regions, driven by distinct factors. North America is the largest region, accounting for approximately 40% of the market share, driven by high adoption rates, favorable policies, and significant investments in healthcare infrastructure.

In contrast, the Asia Pacific region is the fastest-growing, driven by increasing demographics, improving infrastructure, and a maturing ecosystem. Europe also holds a significant share, with key drivers including high adoption rates, stringent policies, and substantial investments in research and development.

Latin America and Middle East & Africa are expected to experience steady regional forecast growth, driven by growing demographics, increasing infrastructure development, and rising adoption of advanced healthcare technologies. Overall, the Targeted PSMA Radionuclide Drug Conjugates market is poised for significant growth, driven by regional factors and a growing demand for innovative treatments.

Competitive Landscape

The Targeted PSMA Radionuclide Drug Conjugates competitive landscape is moderately consolidated, with a mix of global players and local companies competing in the market. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The market is driven by companies seeking to differentiate themselves through innovative products and strong distribution networks, with the Targeted PSMA Radionuclide Drug Conjugates competitive landscape being shaped by these factors.

Companies in the market are adopting various strategies to stay competitive, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. The following companies are focusing on specific strategic areas:

Novartis: regional expansion

Telix Pharmaceutical: innovation pipeline

Lantheus: premium pricing

University of California: local manufacturing

Grand Pharmaceutical: OEM tie-ups

Novartis: vertical integration

Key Targeted PSMA Radionuclide Drug Conjugates Companies5 items

Novartis

Telix Pharmaceutical

Lantheus

University of California

Grand Pharmaceutical

Market Ecosystem

The Targeted PSMA Radionuclide Drug Conjugates ecosystem encompasses a complex network of participants, spanning from upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly segmented into three main categories: upstream, midstream, and downstream, with value being created and captured at each stage. The upstream segment comprises technology providers and suppliers, while the midstream segment involves integrators and channels, and the downstream segment consists of end users.

Raw material/component suppliers — provide essential materials

Technology providers — develop enabling technologies

OEMs / manufacturers — produce final products

System integrators / EPCs — integrate components and systems

Distributors / channel partners — facilitate product distribution

Regulators/standards bodies — establish guidelines and standards

End users / buyers — utilize the final products

In the Targeted PSMA Radionuclide Drug Conjugates ecosystem, value flows through the various stages, with control points existing at the regulatory and technology development levels. Dependency risks arise from input constraints, standards, and approvals, while switching costs and partnerships can influence adoption. The ecosystem's structure and dynamics can differ by region, with varying levels of investment in research and development, as well as distinct regulatory frameworks. Conducting a thorough value chain analysis is essential to understanding the intricacies of this ecosystem and identifying potential bottlenecks and areas for improvement.

Recent Industry Insights

The Targeted PSMA Radionuclide Drug Conjugates industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between pharmaceutical companies to advance the development of targeted therapies, have been a key highlight. Additionally, there have been notable mergers and acquisitions, with companies seeking to expand their portfolios and capabilities in the field.

Furthermore, the industry has seen the launch of new products and technologies, including innovative radiopharmaceuticals designed to improve treatment outcomes for patients. Regulatory changes have also played a crucial role, with updates to guidelines and approvals for new therapies. The Targeted PSMA Radionuclide Drug Conjugates market is expected to continue evolving, driven by shifts in consumer and enterprise trends, as well as funding rounds and expansions that support ongoing research and development.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Targeted PSMA Radionuclide Drug Conjugates market outlook. The market exhibits high attractiveness due to its potential in treating prostate cancer, with a growing demand for innovative and effective therapies. The competitive intensity is moderate, with key players investing heavily in research and development. The long-term outlook is promising, driven by advances in technology and increasing awareness about targeted therapies.

The innovation landscape is rapidly evolving, with ongoing clinical trials and new product launches expected to shape the market. However, the demand-supply balance is a key concern, with potential shortages of critical components. Key risk factors include regulatory challenges, intense competition, and high development costs. Despite these risks, the market is poised for significant growth, offering opportunities for investors and stakeholders.

12 items

1. Executive Summary

2. Targeted PSMA Radionuclide Drug Conjugates Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Targeted PSMA Radionuclide Drug Conjugates Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Targeted PSMA Radionuclide Drug Conjugates Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Targeted PSMA Radionuclide Drug Conjugates Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Targeted PSMA Radionuclide Drug Conjugates Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Targeted PSMA Radionuclide Drug Conjugates Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Targeted PSMA Radionuclide Drug Conjugates Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Targeted PSMA Radionuclide Drug Conjugates Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Targeted PSMA Radionuclide Drug Conjugates Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Targeted PSMA Radionuclide Drug Conjugates Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Targeted PSMA Radionuclide Drug Conjugates Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Targeted PSMA Radionuclide Drug Conjugates Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Targeted PSMA Radionuclide Drug Conjugates Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Targeted PSMA Radionuclide Drug Conjugates Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Targeted PSMA Radionuclide Drug Conjugates Market Competition by Key Manufacturers

9.1. Global Targeted PSMA Radionuclide Drug Conjugates Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Targeted PSMA Radionuclide Drug Conjugates: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Novartis

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Telix Pharmaceutical

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Lantheus

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. University of California

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Grand Pharmaceutical

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Targeted PSMA Radionuclide Drug Conjugates Market

Figure 4: Global Targeted PSMA Radionuclide Drug Conjugates Market: Drivers

Figure 5: Global Targeted PSMA Radionuclide Drug Conjugates Market: Challenges

Figure 6: Global Targeted PSMA Radionuclide Drug Conjugates Market: Trends

Figure 7: Global Targeted PSMA Radionuclide Drug Conjugates Market: Opportunity

Figure 8: Global Targeted PSMA Radionuclide Drug Conjugates Market: Restraint

Figure 9: Global Targeted PSMA Radionuclide Drug Conjugates Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Targeted PSMA Radionuclide Drug Conjugates Market Value (USD Million) By Region

Figure 19: Global Targeted PSMA Radionuclide Drug Conjugates Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Targeted PSMA Radionuclide Drug Conjugates Market Value (USD Million) By Region

Figure 27: Global Targeted PSMA Radionuclide Drug Conjugates Market Share (%) By: Regions (2032)

Figure 28: Global Targeted PSMA Radionuclide Drug Conjugates Market Volume (K) By Region

Figure 29: Global Targeted PSMA Radionuclide Drug Conjugates Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Targeted PSMA Radionuclide Drug Conjugates Market Value (USD Million) By Region

Figure 37: Global Targeted PSMA Radionuclide Drug Conjugates Market Share (%) By: Regions (2032)

Figure 38: Global Targeted PSMA Radionuclide Drug Conjugates Market Volume (K) By Region

Figure 39: Global Targeted PSMA Radionuclide Drug Conjugates Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

105 items

Table 1: Market Segmentation Analysis

Table 2: Global Targeted PSMA Radionuclide Drug Conjugates Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Targeted PSMA Radionuclide Drug Conjugates Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Targeted PSMA Radionuclide Drug Conjugates Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Targeted PSMA Radionuclide Drug Conjugates Market Value (USD Million) By Region

Table 14: Global Targeted PSMA Radionuclide Drug Conjugates Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Targeted PSMA Radionuclide Drug Conjugates Market Volume (K) By Region

Table 31: Global Targeted PSMA Radionuclide Drug Conjugates Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Targeted PSMA Radionuclide Drug Conjugates Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Targeted PSMA Radionuclide Drug Conjugates Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Targeted PSMA Radionuclide Drug Conjugates Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Novartis Basic Information And Sales Area

Table 52: Novartis. Products Portfolio

Table 53: Telix Pharmaceutical Basic Information And Sales Area

Table 54: Telix Pharmaceutical. Products Portfolio

Table 55: Lantheus Basic Information And Sales Area

Table 56: Lantheus. Products Portfolio

Table 57: University of California Basic Information And Sales Area

Table 58: University of California. Products Portfolio

Table 59: Grand Pharmaceutical Basic Information And Sales Area

Table 60: Grand Pharmaceutical. Products Portfolio

Table 61: Global Market Value (USD Million) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Market Value (USD Million) (2025-2032) By Types

Table 64: Global Market Share (%) By Types (2032)

Table 65: Global Market Volume (K) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Volume (K) (2025-2032) By Types

Table 68: Global Market Share (%) By Types (2032)

Table 69: Global Targeted PSMA Radionuclide Drug Conjugates Market Value (USD Million) By Region

Table 70: Global Targeted PSMA Radionuclide Drug Conjugates Market Share (%) By Region (2025-2032)

Table 71: North America Market Value (USD Million) (2025-2032) By Country

Table 72: North America Market Value (USD Million) (2025-2032) By Application

Table 73: North America Market Value (USD Million) (2025-2032) By Types

Table 74: Europe Market Value (USD Million) (2025-2032) By Country

Table 75: Europe Market Value (USD Million) (2025-2032) By Application

Table 76: Europe Market Value (USD Million) (2025-2032) By Types

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 80: South America Market Value (USD Million) (2025-2032) By Country

Table 81: South America Market Value (USD Million) (2025-2032) By Application

Table 82: South America Market Value (USD Million) (2025-2032) By Types

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 86: Global Targeted PSMA Radionuclide Drug Conjugates Market Volume (K) By Region

Table 87: Global Targeted PSMA Radionuclide Drug Conjugates Market Share (%) By Region (2025-2032)

Table 88: North America Market Volume (K) (2025-2032) By Country

Table 89: North America Market Volume (K) (2025-2032) By Application

Table 90: North America Market Volume (K) (2025-2032) By Types

Table 91: Europe Market Volume (K) (2025-2032) By Country

Table 92: Europe Market Volume (K) (2025-2032) By Application

Table 93: Europe Market Volume (K) (2025-2032) By Types

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 95: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 97: South America Market Volume (K) (2025-2032) By Country

Table 98: South America Market Volume (K) (2025-2032) By Application

Table 99: South America Market Volume (K) (2025-2032) By Types

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 101: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 103: Research Programs/Design For This Report

Table 104: Key Data Information From Secondary Sources

Table 105: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Targeted PSMA Radionuclide Drug Conjugates Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.72 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; Telix Pharmaceutical; Lantheus; University of California; Grand Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

High development costs and stringent regulatory requirements are limiting the entry of new players in the Targeted PSMA Radionuclide Drug Conjugates market, thereby restraining market growth

The availability of alternative treatment options, such as hormone therapy and chemotherapy, is also hindering the growth of the Targeted PSMA Radionuclide Drug Conjugates market size

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Targeted PSMA Radionuclide Drug Conjugates Segmentation Breakdown7 items

Application

Hospital

Specialist Clinic

Other

Types

Diagnostic

Therapeutic

Regional Insights

Loading chart…

Competitive Landscape

Novartis: regional expansion

Telix Pharmaceutical: innovation pipeline

Lantheus: premium pricing

University of California: local manufacturing

Grand Pharmaceutical: OEM tie-ups

Novartis: vertical integration

Key Targeted PSMA Radionuclide Drug Conjugates Companies5 items

Novartis

Telix Pharmaceutical

Lantheus

University of California

Grand Pharmaceutical

Market Ecosystem

Raw material/component suppliers — provide essential materials

Technology providers — develop enabling technologies

OEMs / manufacturers — produce final products

System integrators / EPCs — integrate components and systems

Distributors / channel partners — facilitate product distribution

Regulators/standards bodies — establish guidelines and standards

End users / buyers — utilize the final products

Recent Industry Insights

Analyst Overview

Table of Contents